NCT06833931View on ClinicalTrials.gov

A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 17, 2024

Primary Completion Date

May 28, 2025

Study Completion Date

May 28, 2025

Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
DRUG

IV infusion

IV infusion

OTHER

Placebo

IV infusion

Sponsors

Lead Sponsor

PepGen Inc
All Listed Sponsors
lead

PepGen Inc

INDUSTRY

NCT06833931 - A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment | Biotech Hunter | Biotech Hunter